Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps

The percentage of weight loss from fat-free mass with GLP-1 receptor agonists ranges from 20% to 40%.

• Weight loss from GLP-1 receptor agonists is primarily from fat stores, with less than 25% typically being fat-free mass.
• Higher weight loss, such as that achieved through metabolic bariatric surgery, is associated with greater fat-free mass loss.
• The studies analyzed included exenatide, liraglutide, semaglutide, and tirzepatide.
• Variability in fat-free mass loss was noted across 28 clinical trials, with most reporting percentages exceeding 25%.
• Dual-energy X-ray absorptiometry (DXA) was used to measure fat-free mass, though it does not directly assess skeletal muscle mass.
• Advanced imaging techniques combined with functional testing may provide better insights into skeletal muscle quantity and quality.

AI simplified